MULTICELL TECHNOLOGIES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | -99.00% |
|
0.00% | 0.00% |
| 2015 | MultiCell Technologies, Inc. Auditor Raises 'Going Concern' Doubt | CI |
| 2014 | MultiCell Technologies Files Novel Antibody-Drug Conjugate Patent Application | CI |
| Sales 2013 | 49.32K 67.41K | Sales 2014 | 49.32K 67.41K | Capitalization | 2.16M 2.96M |
|---|---|---|---|---|---|
| Net income 2013 | -1M -1.37M | Net income 2014 | - 0 | EV / Sales 2013 | 34.9 x |
| Net cash position 2013 | 39.11K 53.46K | Net Debt 2014 | 90.04K 123K | EV / Sales 2014 | 45.7 x |
| P/E ratio 2013 |
-1.09
x | P/E ratio 2014 |
-4.9
x | Employees | - |
| Yield 2013 * |
-
| Yield 2014 |
-
| Free-Float | 90.01% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -99.00% |
1 month
0.00
0.00
Current year
0.000.00
1 year
0.000.00
3 years
0.000.00
5 years
0.000.01
10 years
0.000.01
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | - | -100.00% | 1,235 |
Delayed Quote OTC Markets, April 16, 2024 at 03:20 pm
More quotes
MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company. The Company and its subsidiaries are developing therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer and interventional cardiology, and peripheral vessel applications. The Company's portfolio of lead drug candidates is in various stages of discovery optimization, and preclinical and clinical development, and includes MCT-125, MCT-465, MCT-475 and MCT-485. MCT-125 is a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue. MCT-465 is a preclinical synthetic double-stranded ribonucleic acid (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers. MCT-475 is a discovery-stage antibody therapeutic candidate used in combination with dsRNA for the treatment of solid tumor cancers. MCT-485 is a discovery-stage dsRNA therapeutic candidate for the treatment of certain cancers.
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 5K | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- MCET Stock
